On the stock market since 2002, it operates in the world of health and science. It has 14,000 employees. Now — the numbers.
This is an established company with proven profits.
The biggest line carries real weight, but it doesn’t decide everything on its own.
Average growth of 6% a year over the last 4 years. Every year shown ended in profit.
If every debt were paid off today, $437.6M would still be left in the vault — a solid cushion for hard times.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
R&D Investment: Spending on future research is low.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
The net profit margin is 16% — still a thick cushion, though costs have been eating into it lately.
There is $517.8M in the vault; even if every debt were paid off, $437.6M would remain.
The company’s market value is 118 times its annual profit. Even a small disappointment could hit the price hard.
The price action doesn’t yet back an upward turn. Council score: 0/10.
The share set aside for the future is small; the pace of new ideas may slow. Council score: 2/10.
On our five-subject report card, SIRO sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: SIRO is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.